These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29474179)

  • 21. Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study.
    Branca M; Costa S; Mariani L; Sesti F; Agarossi A; di Carlo A; Galati M; Benedetto A; Ciotti M; Giorgi C; Criscuolo A; Valieri M; Favalli C; Paba P; Santini D; Piccione E; Alderisio M; De Nuzzo M; di Bonito L; Syrjänen K
    Eur J Gynaecol Oncol; 2004; 25(6):689-98. PubMed ID: 15597844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-Risk Human Papillomavirus Types in Cervical Intraepithelial Neoplasia 2-3 and in Invasive Cervical Cancer Patients.
    Siegler E; Reichman Y; Kugelman N; Mackuli L; Lavie O; Ostrovsky L; Shaked-Mishan P; Segev Y
    J Low Genit Tract Dis; 2019 Oct; 23(4):248-252. PubMed ID: 31592971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic burden of human papillomavirus-related diseases in Italy.
    Baio G; Capone A; Marcellusi A; Mennini FS; Favato G
    PLoS One; 2012; 7(11):e49699. PubMed ID: 23185412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population.
    Henk HJ; Insinga RP; Singhal PK; Darkow T
    J Low Genit Tract Dis; 2010 Jan; 14(1):29-36. PubMed ID: 20040833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Costs of cervical cancer and precancerous lesions treatment in a publicly financed health care system.
    Tang CH; Pwu RF; Tsai IC; Wang HI; You SL; Chen CA; Scuffham PA; Hsieh CY; Chou CY; Lin SR; Chen YD; Chen CJ
    Arch Gynecol Obstet; 2010 Apr; 281(4):683-95. PubMed ID: 19730873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan.
    Yamabe K; Singhal PK; Abe M; Dasbach EJ; Elbasha EH
    Value Health Reg Issues; 2013 May; 2(1):92-97. PubMed ID: 29702859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Model for predicting the burden and cost of treatment in cervical cancer and HPV-related diseases in Thailand.
    Termrungruanglert W; Havanond P; Khemapech N; Lertmaharit S; Pongpanich S; Jirakorbchaipong P; Kitsiripornchai S; Taneepanichskul S
    Eur J Gynaecol Oncol; 2012; 33(4):391-4. PubMed ID: 23091896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,
    Bratti MC; Rodríguez AC; Schiffman M; Hildesheim A; Morales J; Alfaro M; Guillén D; Hutchinson M; Sherman ME; Eklund C; Schussler J; Buckland J; Morera LA; Cárdenas F; Barrantes M; Pérez E; Cox TJ; Burk RD; Herrero R
    Rev Panam Salud Publica; 2004 Feb; 15(2):75-89. PubMed ID: 15030652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment patterns and associated costs for genital warts in Italy.
    Merito M; Largeron N; Cohet C; Timelli L; Boselli F; Matteelli A; Naldi L; Vittori G
    Curr Med Res Opin; 2008 Nov; 24(11):3175-83. PubMed ID: 18851777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
    BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
    Capri S; Gasparini R; Panatto D; Demarteau N
    Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN).
    Acladious NN; Sutton C; Mandal D; Hopkins R; Zaklama M; Kitchener H
    Int J Cancer; 2002 Mar; 98(3):435-9. PubMed ID: 11920596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
    Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G
    Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Burden of HPV related anogenital diseases in young women in Germany - an analysis of German statutory health insurance claims data from 2012 to 2017.
    Reuschenbach M; Mihm S; Wölle R; Schneider KM; Jacob C; Braun S; Greiner W; Hampl M
    BMC Infect Dis; 2020 Apr; 20(1):297. PubMed ID: 32321435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients.
    Dahlstrom KR; Fu S; Chan W; Shelal Z; Ramondetta LM; Lairson DR
    Pharmacoeconomics; 2018 Nov; 36(11):1355-1365. PubMed ID: 30019118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness.
    Melnikow J; Kulasingam S; Slee C; Helms LJ; Kuppermann M; Birch S; McGahan CE; Coldman A; Chan BK; Sawaya GF
    Obstet Gynecol; 2010 Nov; 116(5):1158-70. PubMed ID: 20966702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women.
    Konno R; Sasagawa T; Fukuda T; Van Kriekinge G; Demarteau N
    Int J Gynecol Cancer; 2010 Apr; 20(3):385-92. PubMed ID: 20375802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study.
    Hillemanns P; Breugelmans JG; Gieseking F; Bénard S; Lamure E; Littlewood KJ; Petry KU
    BMC Infect Dis; 2008 Jun; 8():76. PubMed ID: 18518976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Watson M; Lowy DR; Markowitz LE
    Vaccine; 2012 Sep; 30(42):6016-9. PubMed ID: 22867718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus infection, centrosome aberration, and genetic stability in cervical lesions.
    Skyldberg B; Fujioka K; Hellström AC; Sylvén L; Moberger B; Auer G
    Mod Pathol; 2001 Apr; 14(4):279-84. PubMed ID: 11301343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.